Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bubeck

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Strahlentherapie|October 1, 1984
[Radioiodine therapy of differentiated thyroid cancer. 10-year results of a standardized therapy in 269 patients]B Bubeck, B Kimmig, H J Hermann, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1988
Technetium-99m labeled renal function and imaging agents: I. Clinical evaluation of 99mTc CO2-DADS-A (99mTc N,N'-bis-(mercaptoacetyl)-2,3-diaminopropanoate)B Bubeck, W Brandau, F Reinbold, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1988
Technetium-99m labeled renal function and imaging agents: II. Clinical evaluation of 99mTc MAG3 (99mTc mercaptoacetylglycylglycylglycine)B Bubeck, W Brandau, M Steinbächer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1984
Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidineB Kimmig, W E Brandeis, M Eisenhut, et al.
Pediatric Surgery International|January 1, 1997
Recurrent mediastinal mass in a child with Hodgkin's disease following successful therapy: a diagnostic challengeA Feldges, H P Wagner, B Bubeck, et al.
Biological Psychiatry|May 16, 1998
D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatmentJ Schröder, S Silvestri, B Bubeck, et al.
Nuklearmedizin. Nuclear Medicine|August 1, 1991
Non-invasive detection of reduced regional myocardial perfusion at rest in patients with unstable angina pectoris: increased regional 81mKr deposition following intravenous injection of 81RbR Zimmermann, H Tillmanns, B Bubeck, et al.
Zeitschrift Fur Kardiologie|January 1, 1989
[Effects of gallopamil on iodine-123-phenyl-pentadecanoic acid and thallium 201 uptake in patients with coronary heart disease]H Tillmanns, R Zimmermann, M Kapp, et al.
Journal of Cardiovascular Pharmacology|January 1, 1992
Reduction of myocardial ischemia by gallopamil: a dual-isotope study with thallium-201 and iodine-123 phenylpentadecanoic acidR Zimmermann, H Tillmanns, M Kapp, et al.
Circulation|February 15, 1995
Residual 201Tl activity in irreversible defects as a marker of myocardial viability. Clinicopathological studyR Zimmermann, G Mall, B Rauch, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Strahlentherapie|October 1, 1984
[Radioiodine therapy of differentiated thyroid cancer. 10-year results of a standardized therapy in 269 patients]B Bubeck, B Kimmig, H J Hermann, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1988
Technetium-99m labeled renal function and imaging agents: I. Clinical evaluation of 99mTc CO2-DADS-A (99mTc N,N'-bis-(mercaptoacetyl)-2,3-diaminopropanoate)B Bubeck, W Brandau, F Reinbold, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1988
Technetium-99m labeled renal function and imaging agents: II. Clinical evaluation of 99mTc MAG3 (99mTc mercaptoacetylglycylglycylglycine)B Bubeck, W Brandau, M Steinbächer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1984
Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidineB Kimmig, W E Brandeis, M Eisenhut, et al.
Pediatric Surgery International|January 1, 1997
Recurrent mediastinal mass in a child with Hodgkin's disease following successful therapy: a diagnostic challengeA Feldges, H P Wagner, B Bubeck, et al.
Biological Psychiatry|May 16, 1998
D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatmentJ Schröder, S Silvestri, B Bubeck, et al.
Nuklearmedizin. Nuclear Medicine|August 1, 1991
Non-invasive detection of reduced regional myocardial perfusion at rest in patients with unstable angina pectoris: increased regional 81mKr deposition following intravenous injection of 81RbR Zimmermann, H Tillmanns, B Bubeck, et al.
Zeitschrift Fur Kardiologie|January 1, 1989
[Effects of gallopamil on iodine-123-phenyl-pentadecanoic acid and thallium 201 uptake in patients with coronary heart disease]H Tillmanns, R Zimmermann, M Kapp, et al.
Journal of Cardiovascular Pharmacology|January 1, 1992
Reduction of myocardial ischemia by gallopamil: a dual-isotope study with thallium-201 and iodine-123 phenylpentadecanoic acidR Zimmermann, H Tillmanns, M Kapp, et al.
Circulation|February 15, 1995
Residual 201Tl activity in irreversible defects as a marker of myocardial viability. Clinicopathological studyR Zimmermann, G Mall, B Rauch, et al.
Pageof 4